Sodium zirconium cyclosilicate for treating hyperkalaemia

Sodium zirconium cyclosilicate for treating hyperkalaemia – guidance (TA599)
Information type: Drug best practice guidance
Source: National Institute for Health and Care Excellence
Specialities: Emergency medicine and urgent care | Renal and urologic disorders
Summary
Sodium zirconium cyclosilicate is recommended as an option for hyperkalaemia in adults only if used, in emergency care for acute life-threatening disease, or in outpatient care for persistent hyperkalaemia in CKD 3b to 5 or heart failure with restrictions.
UKMi comment
The restrictions to use in outpatient care are that, the confirmed serum potassium level of at least 6.0 mmol/litre and is not taking an optimised dosage of renin-angiotensin-aldosterone system (RAAS) inhibitor because of hyperkalaemia and is not on dialysis.
Related links:

Sodium zirconium cyclosilicate for treating hyperkalaemia – guidance (TA599)